세계의 혈당 측정기 시장 : 제품 유형별, 용도별, 측정 부위별, 최종 사용자별 예측(-2030년)

The global blood glucose monitor market is projected to reach 25.4 billion in 2030 from USD 16.5 billion in 2025, at a CAGR of 9.1% during the forecast period.

The market for blood glucose monitors is expected to grow strongly, driven by demographic, clinical, and technological factors. The rising global prevalence of diabetes, coupled with an expanding geriatric population and increasing awareness of self-monitoring, continues to fuel demand for blood glucose monitoring devices.

Technological advancements, including continuous glucose monitoring (CGM), integration with smartphones and wearables, and AI-based data analytics, have significantly improved accuracy, convenience, and patient engagement, thereby accelerating adoption. Furthermore, supportive government initiatives, improved healthcare infrastructure, and expanding access to home-based monitoring solutions are contributing to market growth. These trends are expected to sustain robust momentum across both developed and emerging economies in the coming years.

Based on product type, the self-monitoring blood glucose systems segment accounted for the largest share in the blood glucose monitor market in 2024.

Based on product type, the global blood glucose monitor market is divided into four main segments: self-monitoring blood glucose systems, continuous glucose monitoring systems, professional point-of-care devices, and non-invasive products. Among these, self-monitoring blood glucose (SMBG) systems have gained the highest adoption due to their optimal balance between accuracy, comfort, and convenience for patients, particularly those managing their condition at home. These devices offer quick and reliable glucose readings with minimal discomfort, encouraging consistent self-monitoring practices. Additionally, advancements such as micro-needle lancets, smaller sample requirements, and improved test strip designs have enhanced their usability. Their compatibility with connected health ecosystems-including smartphone apps, cloud-based data tracking, and telehealth integration-further drives patient engagement and improves healthcare provider oversight. Growing patient preference for affordable, easy-to-use monitoring tools, combined with rising awareness of proactive diabetes management, continues to reinforce the dominance of the SMBG segment across both developed and developing markets.

Based on application, the diabetes management segment is expected to grow at the highest CAGR during the forecast period in the blood glucose monitor market.

The global blood glucose monitor market is segmented by application into three categories: diabetes management, health & wellness monitoring, and other applications. Among these, the diabetes management segment is projected to witness the fastest growth during the forecast period, driven by the rising prevalence of type 1 and type 2 diabetes and the growing need for continuous and precise glucose tracking. The increasing adoption of continuous glucose monitoring (CGM) systems, which offer real-time insights, has enabled improved insulin dosing, dietary management, and lifestyle optimization. The integration of monitoring devices with digital health platforms, mobile applications, and cloud-based analytics enables remote consultations, automated alerts, and seamless data sharing with healthcare professionals, thereby supporting personalized diabetes care. Moreover, the growing emphasis on preventive healthcare, early disease detection, and supportive reimbursement programs is encouraging the adoption of regular monitoring. The availability of compact, user-friendly, and connected home monitoring devices empowers patients to independently manage their glucose levels, ensuring better compliance and reducing the risk of severe complications. Additionally, the rising consumer focus on health optimization and metabolic wellness is expanding the use of glucose monitors beyond traditional diabetes management, further amplifying market growth.

North America is expected to register the highest share of the blood glucose monitor market during the forecast period.

The global blood glucose monitor market is divided into six main regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC Countries.

North America accounted for the largest share of the global blood glucose monitor market, driven by its advanced healthcare infrastructure, high diabetes prevalence, and strong adoption of digital health technologies. The region benefits from the widespread availability of continuous glucose monitoring (CGM) systems, favorable reimbursement frameworks, and increased awareness of diabetes management and preventive care. Moreover, the strong presence of leading market players, continuous product innovation, and strategic collaborations between healthcare providers and technology companies further reinforce North America's leadership position. Rising healthcare expenditure, growing geriatric population, and the rapid integration of connected and AI-enabled glucose monitoring devices continue to support sustained market growth across the region.

A breakdown of the primary participants (supply side) for the blood glucose monitor market referred to in this report is provided below:

• By Company Type: Tier 1 (30%), Tier 2 (35%), and Tier 3 (35%)
• By Designation: C-level Executives (20%), Directors (35%), and Others (45%)
• By Region: North America (30%), Europe (25%), Asia Pacific (20%), Latin America (20%), Middle East & Africa (2%), GCC Countries (3%)

Prominent players in the blood glucose monitor market include Abbott Laboratories (US), Dexcom, Inc. (US), Medtronic (Ireland), B.Braun SE (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Ascensia Diabetes Care Holdings AG (Switzerland), Senseonics (US), Nipro (Japan), Medical Technology and Devices S.p.A. (Italy), Terumo Corporation (Japan), i-SENS, Inc. (South Korea), Sinocare (China), Nemaura Medical Inc. (UK), ACON Laboratories, Inc. (US), LifeScan IP Holdings, LLC (US), Ultrahuman Healthcare Pvt Ltd. (India), LifePlus (US), Prodigy Diabetes Care, LLC (US), A. Menarini Diagnostics S.r.l (Italy), Beurer GmbH (Germany), Oura Health Oy (Finland), SD Biosensor, INC (South Korea), Agatsa (India), Rossmax International Ltd (US), and Medisana Gmbh (Germany).

Research Coverage

The report provides an analysis of the blood glucose monitor market, focusing on estimating the market size and potential for future growth across various segments, including products, applications, test sites, regions, and end users. Additionally, the report features a competitive analysis of the key players in the market, detailing their company profiles, product & service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report provides valuable insights for market leaders and new entrants in the blood glucose monitor industry, offering approximate revenue figures for the overall market and its subsegments. It assists stakeholders in understanding the competitive landscape, enabling them to better position their businesses and develop effective go-to-market strategies. Additionally, the report highlights key market drivers, restraints, challenges, and opportunities, enabling stakeholders to assess the current state of the market.

This report provides insights into the following pointers:

• Analysis of key drivers (Increasing prevalence of diabetes, Growing elderly population and increasing life expectancy, Rise in R&D investments and launch of technologically advanced products, wellness & preventive use of CGMs beyond diabetes), restraints (High cost and socioeconomic disparities in access to blood glucose sensors, Short sensor lifespan and frequent replacements), opportunities (Integration with digital health platforms and smart devices, Expansion of coverage and reimbursement policies for CGMs) and challenges (Regulatory compliance challenges for non-invasive glucose monitoring technologies, Data overload & alarm fatigue).
• Market Penetration: It provides detailed information on the product portfolios offered by major players in the global blood glucose monitor market. The report covers various segments, including product type, application, test site, end user, and region.
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global blood glucose monitor market.
• Market Development: Thorough knowledge and analysis of the profitable rising markets by product type, application, test site, end user, and region.
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global blood glucose monitor market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global blood glucose monitor market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Objectives of primary research
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 TOP-DOWN APPROACH (BASED ON UTILIZATION RATE AND ADOPTION PATTERN)
• 2.3 DATA TRIANGULATION
• 2.4 RESEARCH LIMITATIONS
  • 2.4.1 SCOPE-RELATED LIMITATIONS
  • 2.4.2 METHODOLOGY-RELATED LIMITATIONS
• 2.5 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BLOOD GLUCOSE MONITOR MARKET OVERVIEW
• 4.2 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE AND COUNTRY (2024)
• 4.3 BLOOD GLUCOSE MONITOR MARKET: GEOGRAPHICAL MIX
• 4.4 BLOOD GLUCOSE MONITOR MARKET: REGIONAL MIX (2025-2030)
• 4.5 BLOOD GLUCOSE MONITOR MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of diabetes
    • 5.2.1.2 Growing elderly population and increasing life expectancy
    • 5.2.1.3 Rise in R&D investments and launch of technologically advanced products
    • 5.2.1.4 Wellness & preventive use of CGMs beyond diabetes
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost and socioeconomic disparities in access to blood glucose sensors
    • 5.2.2.2 Short sensor lifespan and frequent replacements
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Integration with digital health platforms and smart devices
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Regulatory and compliance challenges for non-invasive glucose monitoring technologies
    • 5.2.4.2 Data overload & alarm fatigue
    • 5.2.4.3 Financial burden and coverage gaps
• 5.3 UNMET NEEDS & WHITE SPACES
  • 5.3.1 UNMET NEEDS IN BLOOD GLUCOSE MONITOR MARKET
  • 5.3.2 WHITE SPACE OPPORTUNITIES
• 5.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 5.4.1 INTERCONNECTED MARKETS
  • 5.4.2 CROSS-SECTOR OPPORTUNITIES

6 INDUSTRY TRENDS

• 6.1 PORTER'S FIVE FORCES ANALYSIS
  • 6.1.1 THREAT OF NEW ENTRANTS
  • 6.1.2 INTENSITY OF COMPETITIVE RIVALRY
  • 6.1.3 BARGAINING POWER OF BUYERS
  • 6.1.4 BARGAINING POWER OF SUPPLIERS
  • 6.1.5 THREAT OF SUBSTITUTES
• 6.2 MACROECONOMIC OUTLOOK
  • 6.2.1 INTRODUCTION
  • 6.2.2 GDP TRENDS AND FORECAST
  • 6.2.3 TRENDS IN DIABETES CARE INDUSTRY
  • 6.2.4 TRENDS IN GLOBAL INSULIN DELIVERY SYSTEMS INDUSTRY
• 6.3 SUPPLY CHAIN ANALYSIS
• 6.4 VALUE CHAIN ANALYSIS
• 6.5 ECOSYSTEM ANALYSIS
  • 6.5.1 ROLE IN ECOSYSTEM
• 6.6 PRICING ANALYSIS
  • 6.6.1 AVERAGE SELLING PRICE OF BLOOD GLUCOSE MONITORS, BY PRODUCT, 2024
  • 6.6.2 AVERAGE SELLING PRICE TREND OF SELF-MONITORING BLOOD GLUCOSE SYSTEMS, BY REGION, 2022-2024
  • 6.6.3 PRODUCT PURCHASE CYCLE, BY PRODUCT SEGMENT
• 6.7 TRADE ANALYSIS
  • 6.7.1 IMPORT DATA FOR HS CODE 9027, 2020-2024
  • 6.7.2 EXPORT DATA FOR HS CODE 9027, 2020-2024
• 6.8 KEY CONFERENCES & EVENTS, 2025-2026
• 6.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 6.10 INVESTMENT & FUNDING SCENARIO
• 6.11 CASE STUDY ANALYSIS
  • 6.11.1 CASE STUDY 1: LONG-TERM GLUCOSE MONITORING FOR SENSITIVE SKIN PATIENTS USING SENSEONICS' EVERSENSE E3 IMPLANTABLE SENSOR
  • 6.11.2 CASE STUDY 2: ENHANCING PATIENT ADHERENCE AND GLYCEMIC CONTROL USING ABBOTT'S FREESTYLE LIBRE 2 CGM
  • 6.11.3 CASE STUDY 3: IMPROVING GLYCEMIC CONTROL WITH DEXCOM G6 CGM SYSTEM
• 6.12 IMPACT OF 2025 US TARIFFS ON BLOOD GLUCOSE MONITOR MARKET
  • 6.12.1 INTRODUCTION
  • 6.12.2 KEY TARIFF RATES
  • 6.12.3 PRICE IMPACT ANALYSIS
  • 6.12.4 IMPACT ON REGION
    • 6.12.4.1 US
    • 6.12.4.2 Europe
    • 6.12.4.3 Asia Pacific
  • 6.12.5 IMPACT ON END-USE INDUSTRIES

7 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL AND AI ADOPTION

• 7.1 KEY EMERGING TECHNOLOGIES
• 7.2 COMPLEMENTARY TECHNOLOGIES
  • 7.2.1 BATTERY AND ENERGY HARVESTING INNOVATIONS
• 7.3 TECHNOLOGY/PRODUCT ROADMAP
  • 7.3.1 SHORT TERM (2025-2027) | FOUNDATION & EARLY COMMERCIALIZATION
  • 7.3.2 MID TERM (2027-2030) | EXPANSION & STANDARDIZATION
  • 7.3.3 LONG TERM (2030-2035+) | MASS COMMERCIALIZATION & DISRUPTION
• 7.4 PATENT ANALYSIS
  • 7.4.1 PATENT PUBLICATION TRENDS FOR BLOOD GLUCOSE MONITOR MARKET
  • 7.4.2 TOP APPLICANTS (COMPANIES) OF BLOOD GLUCOSE MONITOR PATENTS
  • 7.4.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN BLOOD GLUCOSE MONITOR MARKET
  • 7.4.4 LIST OF MAJOR PATENTS
• 7.5 PIPELINE ANALYSIS
• 7.6 IMPACT OF AI/GEN AI ON BLOOD GLUCOSE MONITOR MARKET
  • 7.6.1 TOP USE CASES AND MARKET POTENTIAL
  • 7.6.2 TOP CASE STUDIES OF AI IMPLEMENTATION IN BLOOD GLUCOSE MONITOR MARKET
  • 7.6.3 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS
  • 7.6.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN BLOOD GLUCOSE MONITOR MARKET
• 7.7 SUCCESS STORIES & REAL-WORLD APPLICATIONS
  • 7.7.1 ABBOTT: FREESTYLE LIBRE 3-MINIATURIZED SENSOR WITH REAL-TIME CONNECTIVITY
  • 7.7.2 DEXCOM: G7 SENSOR-ADVANCED ALGORITHM FOR ACCURATE AND FAST GLUCOSE READINGS
  • 7.7.3 SENSEONICS: EVERSENSE E3-LONG-TERM IMPLANTABLE CGM WITH SMART ALERTS

8 TREATMENT & REGULATORY LANDSCAPE

• 8.1 REGIONAL REGULATIONS & COMPLIANCE
  • 8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 8.1.2 REGULATORY STANDARDS
    • 8.1.2.1 North America
      • 8.1.2.1.1 US
      • 8.1.2.1.2 Canada
    • 8.1.2.2 Europe
    • 8.1.2.3 Asia Pacific
      • 8.1.2.3.1 China
      • 8.1.2.3.2 Japan
      • 8.1.2.3.3 India
    • 8.1.2.4 Latin America
      • 8.1.2.4.1 Brazil
      • 8.1.2.4.2 Mexico
    • 8.1.2.5 Middle East
    • 8.1.2.6 Africa
• 8.2 EPIDEMIOLOGY OF DIABETES, BY KEY COUNTRY
• 8.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
  • 8.3.1 CERTIFICATIONS, LABELING, AND ECO-STANDARDS IN BLOOD GLUCOSE MONITOR MARKET
• 8.4 TREATMENT AND REGULATORY LANDSCAPE
  • 8.4.1 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

9 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 9.1 DECISION-MAKING PROCESS
• 9.2 KEY STAKEHOLDERS & BUYING CRITERIA
  • 9.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 9.2.2 KEY BUYING CRITERIA
• 9.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 9.4 UNMET NEEDS OF END USERS
• 9.5 MARKET PROFITABILITY
  • 9.5.1 REVENUE POTENTIAL
  • 9.5.2 COST DYNAMICS
  • 9.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

10 BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE

• 10.1 INTRODUCTION
• 10.2 SELF-MONITORING BLOOD GLUCOSE SYSTEMS
  • 10.2.1 GLUCOMETERS
    • 10.2.1.1 Regulatory reinforcement and digital integration to drive advancements in market
  • 10.2.2 TESTING STRIPS
    • 10.2.2.1 Shift toward non-invasive methods for blood glucose monitoring to restrain market growth
  • 10.2.3 LANCETS & LANCING DEVICES
    • 10.2.3.1 Rising focus on reducing chances of infection to increase popularity of safety lancets
• 10.3 CONTINUOUS GLUCOSE MONITORING SYSTEMS
  • 10.3.1 SENSORS
    • 10.3.1.1 Technological advancements and expanding use in diabetes management to boost market growth
  • 10.3.2 IMPLANTS
    • 10.3.2.1 Rising demand for long-duration sensors offering extended lifespan and reduced replacement frequency to drive growth
  • 10.3.3 TRANSMITTERS & RECEIVERS
    • 10.3.3.1 Integration with smart monitoring systems and interoperable diabetes management platforms to fuel growth
• 10.4 PROFESSIONAL POINT-OF-CARE DEVICES
  • 10.4.1 ADVANCING PATIENT CARE THROUGH DECENTRALIZED POINT-OF-CARE GLUCOSE MONITORING TO BOOST MARKET
• 10.5 NON-INVASIVE PRODUCTS
  • 10.5.1 RISING PATIENT PREFERENCE FOR PAINLESS TECHNOLOGY TO FOSTER DEVELOPMENT AND ADOPTION IN FUTURE

11 BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE

• 11.1 INTRODUCTION
• 11.2 FINGERTIP
  • 11.2.1 HIGH ACCURACY ASSOCIATED WITH FINGERTIP TESTING TO SUPPORT MARKET GROWTH
• 11.3 UPPER ARM
  • 11.3.1 RISE OF CONTINUOUS AND MINIMALLY INVASIVE MONITORING TECHNOLOGIES TO BOOST DEMAND FOR UPPER ARM TESTING
• 11.4 OTHER TEST SITES

12 BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION

• 12.1 INTRODUCTION
• 12.2 DIABETES MANAGEMENT
  • 12.2.1 TYPE 1 DIABETES
    • 12.2.1.1 Intensive management needs associated with type 1 diabetes to boost adoption
  • 12.2.2 TYPE 2 DIABETES
    • 12.2.2.1 High prevalence of type 2 diabetes to drive market demand
• 12.3 HEALTH & WELLNESS MONITORING
  • 12.3.1 EMERGING ROLE OF HEALTH & WELLNESS MONITORING FOR BLOOD GLUCOSE MONITORS TO DRIVE MARKET GROWTH
• 12.4 OTHER APPLICATIONS

13 BLOOD GLUCOSE MONITOR MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 SELF/HOME CARE
  • 13.2.1 CONVENIENT, COST-EFFECTIVE, AND FREQUENT MONITORING ASSOCIATED WITH HOME CARE SETTINGS TO DRIVE MARKET
• 13.3 HOSPITALS & CLINICS
  • 13.3.1 STRATEGIC ADOPTION OF BLOOD GLUCOSE SENSORS IN HOSPITALS & CLINICS TO DRIVE MARKET VALIDATION AND GROWTH
• 13.4 OTHER END USERS

14 BLOOD GLUCOSE MONITOR MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 14.2.2 US
    • 14.2.2.1 US to account for largest share of North American blood glucose monitor market
  • 14.2.3 CANADA
    • 14.2.3.1 Rising government support to boost blood glucose monitor market in Canada
• 14.3 EUROPE
  • 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 14.3.2 GERMANY
    • 14.3.2.1 Germany to dominate European blood glucose monitor market
  • 14.3.3 UK
    • 14.3.3.1 Government support and research funding to drive blood glucose monitor market growth in UK
  • 14.3.4 FRANCE
    • 14.3.4.1 High insurance coverage and increasing affordability to support market growth
  • 14.3.5 ITALY
    • 14.3.5.1 Increasing government spending to drive market growth in Italy
  • 14.3.6 SPAIN
    • 14.3.6.1 High diabetes prevalence to drive market growth in Spain
  • 14.3.7 REST OF EUROPE (ROE)
• 14.4 ASIA PACIFIC
  • 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 14.4.2 CHINA
    • 14.4.2.1 China to dominate Asia Pacific blood glucose monitor market
  • 14.4.3 JAPAN
    • 14.4.3.1 Rising aging population and high number of diabetes cases to drive market growth in Japan
  • 14.4.4 INDIA
    • 14.4.4.1 Rising diabetes cases and affordable local manufacturing to fuel insulin device demand in India
  • 14.4.5 AUSTRALIA
    • 14.4.5.1 Government subsidies to drive market
  • 14.4.6 SOUTH KOREA
    • 14.4.6.1 Rising diabetes cases across country to boost market
  • 14.4.7 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 14.5.2 BRAZIL
    • 14.5.2.1 Brazil to account for largest share of Latin American blood glucose monitor market
  • 14.5.3 MEXICO
    • 14.5.3.1 Rising diabetes prevalence to drive market growth
  • 14.5.4 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST & AFRICA
  • 14.6.1 INTERNATIONAL AID PROGRAMS AND GOVERNMENT-LED INITIATIVES FOR NON-COMMUNICABLE DISEASE MANAGEMENT TO FOSTER GROWTH
  • 14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 14.7 GCC COUNTRIES
  • 14.7.1 RISING DIABETES PREVALENCE TO DRIVE MARKET IN GCC COUNTRIES
  • 14.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BLOOD GLUCOSE MONITOR MARKET
• 15.3 REVENUE ANALYSIS, 2020-2024
• 15.4 MARKET SHARE ANALYSIS, 2024
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Product type footprint
    • 15.5.5.4 Test site footprint
    • 15.5.5.5 Application footprint
• 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 RESPONSIVE COMPANIES
  • 15.6.3 DYNAMIC COMPANIES
  • 15.6.4 STARTING BLOCKS
  • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 15.6.5.1 Detailed list of key startups/SMEs
    • 15.6.5.2 Competitive benchmarking of key startups/SMEs
• 15.7 COMPANY VALUATION & FINANCIAL METRICS
  • 15.7.1 FINANCIAL METRICS
  • 15.7.2 COMPANY VALUATION
• 15.8 BRAND/PRODUCT COMPARISON
• 15.9 R&D EXPENDITURE OF KEY PLAYERS
• 15.10 COMPETITIVE SCENARIO
  • 15.10.1 PRODUCT LAUNCHES & APPROVALS
  • 15.10.2 DEALS
  • 15.10.3 EXPANSIONS
  • 15.10.4 OTHER DEVELOPMENTS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 ABBOTT LABORATORIES
    • 16.1.1.1 Business overview
    • 16.1.1.2 Products offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Product launches & approvals
      • 16.1.1.3.2 Deals
      • 16.1.1.3.3 Expansions
      • 16.1.1.3.4 Other developments
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Right to win
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses & competitive threats
  • 16.1.2 DEXCOM, INC.
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Product launches & approvals
      • 16.1.2.3.2 Deals
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Right to win
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses & competitive threats
  • 16.1.3 MEDTRONIC
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Product approvals
      • 16.1.3.3.2 Deals
      • 16.1.3.3.3 Expansions
      • 16.1.3.3.4 Other developments
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Right to win
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses & competitive threats
  • 16.1.4 SINOCARE
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Product approvals
      • 16.1.4.3.2 Deals
      • 16.1.4.3.3 Other developments
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Right to win
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses & competitive threats
  • 16.1.5 ROCHE DIABETES CARE
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Product launches & approvals
      • 16.1.5.3.2 Expansions
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Right to win
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses & competitive threats
  • 16.1.6 B. BRAUN SE
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products offered
  • 16.1.7 I-SENS, INC.
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Product approvals
      • 16.1.7.3.2 Deals
  • 16.1.8 SENSEONICS
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Product launches & approvals
      • 16.1.8.3.2 Deals
      • 16.1.8.3.3 Other developments
  • 16.1.9 ASCENSIA DIABETES CARE HOLDINGS AG
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Product launches
      • 16.1.9.3.2 Deals
  • 16.1.10 NIPRO
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Expansions
  • 16.1.11 NEMAURA MEDICAL INC.
    • 16.1.11.1 Business overview
    • 16.1.11.2 Products offered
    • 16.1.11.3 Recent developments
      • 16.1.11.3.1 Other developments
  • 16.1.12 MEDICAL TECHNOLOGY AND DEVICES S.P.A.
    • 16.1.12.1 Business overview
    • 16.1.12.2 Products offered
    • 16.1.12.3 Recent developments
      • 16.1.12.3.1 Deals
  • 16.1.13 TERUMO CORPORATION
    • 16.1.13.1 Business overview
    • 16.1.13.2 Products offered
    • 16.1.13.3 Recent developments
      • 16.1.13.3.1 Deals
      • 16.1.13.3.2 Expansions
      • 16.1.13.3.3 Other developments
  • 16.1.14 LIFESCAN IP HOLDINGS, LLC
    • 16.1.14.1 Business overview
    • 16.1.14.2 Products offered
    • 16.1.14.3 Recent developments
      • 16.1.14.3.1 Deals
• 16.2 OTHER PLAYERS
  • 16.2.1 ACON LABORATORIES, INC.
  • 16.2.2 LIFEPLUS
  • 16.2.3 PRODIGY DIABETES CARE, LLC
  • 16.2.4 ULTRAHUMAN HEALTHCARE PVT. LTD.
  • 16.2.5 BEURER GMBH
  • 16.2.6 OURA HEALTH OY
  • 16.2.7 SD BIOSENSOR, INC.
  • 16.2.8 A. MENARINI DIAGNOSTICS S.R.L
  • 16.2.9 MEDISANA GMBH
  • 16.2.10 AGATSA
  • 16.2.11 ROSSMAX INTERNATIONAL LTD.

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS